<DOC>
	<DOCNO>NCT01712490</DOCNO>
	<brief_summary>This open-label , randomize , 2-arm , multicenter , phase 3 study primary objective comparing modify progression-free survival ( mPFS ) obtain brentuximab vedotin ( ADCETRIS® ) plus AVD ( doxorubicin [ Adriamycin ] , vinblastine , dacarbazine ; abbreviate A+AVD ) versus obtain ABVD ( doxorubicin [ Adriamycin ] , bleomycin , vinblastine , dacarbazine ) frontline treatment advance classical Hodgkin lymphoma ( HL )</brief_summary>
	<brief_title>Phase 3 Frontline Therapy Trial Patients With Advanced Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Treatmentnaïve Histologically confirm classical Hodgkin Lymphoma ( HL ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Bidimensional measurable disease Nodular lymphocyte predominant Hodgkin lymphoma Cerebral/meningeal disease , include sign symptom progressive multifocal leukoencephalopathy ( PML ) Pulmonary diffusion capacity &gt; 25 % low normal predict value Sensory motor peripheral neuropathy Known human immunodeficiency virus ( HIV ) positive Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection Please note additional exclusion criterion . The study center determine meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Hodgkins Lymphoma</keyword>
	<keyword>Antibody , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD-30</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , Classical</keyword>
	<keyword>ECHELON-1</keyword>
</DOC>